Author: Kaur, Parveen; Chu, Justin Jang Hann
Title: Chikungunya virus: an update on antiviral development and challenges Cord-id: tcy7jrth Document date: 2013_5_15
ID: tcy7jrth
Snippet: Chikungunya virus (CHIKV) has re-emerged as a significant public health threat since the 2005 chikungunya fever epidemic in La Réunion. Driven by the medical importance of this virus, as well as the lack of approved antivirals, research into the field of CHIKV antivirals has recently intensified. Potential therapeutics that have been reported to show anti-CHIKV activity in vitro range from known broad-spectrum antivirals like chloroquine to novel strategies involving RNA silencing technology. A
Document: Chikungunya virus (CHIKV) has re-emerged as a significant public health threat since the 2005 chikungunya fever epidemic in La Réunion. Driven by the medical importance of this virus, as well as the lack of approved antivirals, research into the field of CHIKV antivirals has recently intensified. Potential therapeutics that have been reported to show anti-CHIKV activity in vitro range from known broad-spectrum antivirals like chloroquine to novel strategies involving RNA silencing technology. Although most of the earlier efforts focused on compounds that target host components, some recent studies have reported viral targets such as nonstructural proteins. This article examines the reported in vitro and in vivo efficacies, as well as the therapeutic potential of these antiviral compounds.
Search related documents:
Co phrase search for related documents- active site and acute respiratory syndrome coronavirus: 1, 2, 3, 4, 5, 6, 7, 8, 9, 10, 11, 12, 13, 14, 15, 16, 17, 18, 19, 20, 21, 22, 23, 24, 25, 26, 27, 28, 29, 30, 31, 32, 33, 34, 35, 36, 37, 38, 39, 40, 41, 42, 43, 44, 45, 46, 47, 48, 49, 50, 51, 52, 53, 54, 55, 56, 57, 58, 59, 60, 61, 62, 63, 64, 65, 66, 67, 68, 69, 70, 71, 72
- active site and acute treatment: 1
- active site and additional mechanism: 1
- active site and long duration: 1, 2
- active site and low toxicity: 1, 2
- acute infection and additional mechanism: 1, 2, 3
- acute infection and long duration: 1, 2, 3, 4
- acute infection and low toxicity: 1, 2, 3
- acute infection and luciferase gene: 1, 2
- acute infection and macaque model: 1, 2, 3, 4, 5, 6, 7, 8, 9, 10, 11
- acute infection and maculopapular rash: 1, 2, 3
- acute infection and maculopapular rash headache: 1
- acute phase and long duration: 1, 2, 3, 4, 5, 6
- acute phase and macaque model: 1, 2
- acute respiratory syndrome coronavirus and additional mechanism: 1, 2, 3, 4, 5, 6, 7
- acute respiratory syndrome coronavirus and long duration: 1, 2, 3, 4, 5, 6, 7, 8, 9, 10, 11, 12, 13, 14, 15, 16, 17
- acute respiratory syndrome coronavirus and low toxicity: 1, 2, 3, 4, 5, 6, 7, 8, 9, 10, 11, 12, 13, 14, 15, 16, 17, 18, 19, 20, 21
- acute respiratory syndrome coronavirus and luciferase gene: 1, 2, 3, 4, 5, 6, 7, 8, 9, 10, 11, 12, 13, 14
- acute respiratory syndrome coronavirus and macaque model: 1, 2, 3, 4, 5, 6, 7, 8, 9, 10, 11, 12
Co phrase search for related documents, hyperlinks ordered by date